Artelo Biosciences Inc Stock Price, News & Analysis

Artelo Biosciences (NASDAQ:ARLT) will present at the MicroCap Rodeo Spring Into Action - Best Ideas Virtual Investor Conference, scheduled from May 16-20, 2022. CEO Gregory D. Gorgas will speak on May 16, 2022, at 2:00 p.m. ET, with a live webcast available for replay. Artelo focuses on developing therapeutics that modulate lipid-signaling pathways, targeting conditions like cancer and PTSD. Qualified investors can schedule one-on-one meetings for further discussions. For more details, visit www.artelobio.com.

Artelo Biosciences (Nasdaq: ARTL) reported financial and operational results for Q1 2022, maintaining approximately $23.5 million in cash and investments, expected to support operations into late 2023. The net loss increased to $2.0 million or $0.05 per share, compared to $1.7 million or $0.09 per share in Q1 2021. The company anticipates results from the Phase 1b CAReS trial concerning ART27.13, aimed at treating cancer-related anorexia, in Q3 2022. Ongoing collaborations and positive pre-clinical data were highlighted, with a focus on addressing cancer anorexia cachexia syndrome.

Artelo Biosciences (Nasdaq: ARTL) announced promising pre-clinical results for ART27.13, indicating its potential in treating cancer-related muscle degeneration (cachexia). Research from Trinity College Dublin reveals that ART27.13 acts as a G-Protein Coupled Receptor agonist, targeting both CB₁ and CB₂ receptors. This could address significant patient needs, as cachexia impacts up to 80% of advanced cancer patients. ART27.13 is currently involved in the ongoing CAReS study for cancer appetite recovery.

Artelo Biosciences (Nasdaq: ARTL) announced a collaboration with Dr. Richard K. Porter at Trinity College Dublin to explore the role of fatty acid binding protein (FABP) inhibition in cancer treatment. This partnership aims to enhance understanding of FABP inhibitors and their potential for various tumors, which could lead to new treatments targeting unmet medical needs. The research is expected to yield multiple data readouts over the next year, reinforcing ART26.12's promise in oncology while expanding its compound library for targeted therapies.

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company, announced its invitation to present at the 2022 Virtual Growth Conference on March 28-30, hosted by Maxim Group LLC and M-Vest. The event will feature company presentations, including updates from CEO Gregory Gorgas. Attendees must register as M-Vest members to participate. Artelo focuses on developing therapeutics that target lipid-signaling pathways and the endocannabinoid system, aiming to address significant medical needs in areas like anorexia, cancer, PTSD, and pain management.

Artelo Biosciences (Nasdaq: ARTL) reported a cash balance of $25.6 million as of December 31, 2021, sufficient to fund operations into H2 2023. The company's net loss for the four-month period was $4.0 million, or $0.12 per share, an increase from a net loss of $2.1 million in the same period in 2020. Key milestones include upcoming Phase 1 data for their ART27.13 program targeting cancer-related anorexia, with significant commercial potential in a market valued over $2 billion. The UK classification of ART27.13 as a non-controlled substance enhances its clinical development prospects.

Artelo Biosciences (NASDAQ: ARTL) announced it has been granted a Notice of Allowance by the U.S. Patent and Trademark Office for patent application 16/835,383, concerning the cocrystal composition of cannabidiol (CBD) under its ART12.11 program. This patent strengthens Artelo's intellectual property portfolio and claims methods for treating various serious conditions, including PTSD and cancer, with a potential patent term extending until 2038. The company aims to utilize its patents to advance treatments for significant unmet medical needs in large markets.

Artelo Biosciences (Nasdaq: ARTL) provided a business update and financial results for the first quarter of its fiscal year ending November 30, 2021. The company is advancing its Cancer Appetite Recovery Study (CAReS) for ART27.13, aiming to complete Phase 1 enrollment by Q1 2022. Financially, Artelo reported a net loss of approximately $2.55 million and operating expenses of $2.55 million, up from $1.44 million year-over-year. Cash and marketable securities stood at $26.4 million as of November 30, 2021, an increase from $10.07 million in August 2021.

Artelo Biosciences (Nasdaq: ARTL) announced that the UK Home Office has reclassified its lead clinical cannabinoid, ART27.13, as 'non-controlled.' This decision allows for unhindered production and supply, enhancing the drug's potential in clinical trials. ART27.13 is currently being evaluated in the Phase 1/2 Cancer Appetite Recovery Study (CAReS), targeting anorexia in cancer patients, a condition affecting up to 60% of advanced-stage patients. The drug has shown promise in previous studies for increasing body weight without CNS side effects.